Search

Search Constraints

You searched for: Author/Creator Vogelzang, Nicholas J.

Search Results

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016. (8th December 2016)

2. A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma. (May 2014)

3. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. (September 2017)

4. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Issue 14 (5th April 2019)

6. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013)

7. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013)

8. Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805. Issue 12 (10th May 2022)

9. Association Between Caregiver-Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the Oncologist. (11th August 2021)

10. Association Between Caregiver‐Oncologist Discordance in Patient's Life Expectancy Estimates and Caregiver Perceived Autonomy Support by the Oncologist. (11th August 2021)